Utilizing a Dynamical Description of IspH to Aid in the Development of Novel Antimicrobial Drugs

Blachly, Patrick G.; de Oliveira, César A. F.; Williams, Sarah L.; McCammon, J. Andrew
December 2013
PLoS Computational Biology;Dec2013, Vol. 9 Issue 12, p1
Academic Journal
The nonmevalonate pathway is responsible for isoprenoid production in microbes, including H. pylori, M. tuberculosis and P. falciparum, but is nonexistent in humans, thus providing a desirable route for antibacterial and antimalarial drug discovery. We coordinate a structural study of IspH, a [4Fe-4S] protein responsible for converting HMBPP to IPP and DMAPP in the ultimate step in the nonmevalonate pathway. By performing accelerated molecular dynamics simulations on both substrate-free and HMBPP-bound [Fe4S4]2+ IspH, we elucidate how substrate binding alters the dynamics of the protein. Using principal component analysis, we note that while substrate-free IspH samples various open and closed conformations, the closed conformation observed experimentally for HMBPP-bound IspH is inaccessible in the absence of HMBPP. In contrast, simulations with HMBPP bound are restricted from accessing the open states sampled by the substrate-free simulations. Further investigation of the substrate-free simulations reveals large fluctuations in the HMBPP binding pocket, as well as allosteric pocket openings – both of which are achieved through the hinge motions of the individual domains in IspH. Coupling these findings with solvent mapping and various structural analyses reveals alternative druggable sites that may be exploited in future drug design efforts.


Related Articles

  • Biochemistry of the non-mevalonate isoprenoid pathway. Gräwert, Tobias; Groll, Michael; Rohdich, Felix; Bacher, Adelbert; Eisenreich, Wolfgang // Cellular & Molecular Life Sciences;Dec2011, Vol. 68 Issue 23, p3797 

    The non-mevalonate pathway of isoprenoid (terpenoid) biosynthesis is essential in many eubacteria including the major human pathogen, Mycobacterium tuberculosis, in apicomplexan protozoa including the Plasmodium spp . causing malaria, and in the plastids of plants. The metabolic route is absent...

  • Lipophilic Prodrugs of FR900098 Are Antimicrobial against Francisella novicida In Vivo and In Vitro and Show GlpT Independent Efficacy. McKenney, Elizabeth S.; Sargent, Michelle; Khan, Hameed; Uh, Eugene; Jackson, Emily R.; San Jose, Géraldine; Couch, Robin D.; Dowd, Cynthia S.; van Hoek, Monique L. // PLoS ONE;Oct2012, Vol. 7 Issue 10, Special section p1 

    Bacteria, plants, and algae produce isoprenoids through the methylerythritol phosphate (MEP) pathway, an attractive pathway for antimicrobial drug development as it is present in prokaryotes and some lower eukaryotes but absent from human cells. The first committed step of the MEP pathway is...

  • CHEMEQ DRUG ACTIVE AGAINST GASTRIC ULCER GERM.  // Worldwide Biotech;Apr2003, Vol. 15 Issue 4, p2 

    Focuses on the development of an antimicrobial drug that kills a strain of the gastric ulcer germ, Helicobacter pylori which is resistant to antibiotics, by pharmaceutical company Chemeq Ltd, as of April 2003.

  • Protein Interaction Domain Mapping for the Selection of Validated Targets and Lead Compounds in the Anti-Infectious Area. Legrain, P.; Strosberg, D. // Current Pharmaceutical Design;Jun2002, Vol. 8 Issue 13, p1189 

    Despite considerable progress in the analysis of microbial genomes, the number of validated targets suitable for the development of drugs acting on agents causing infectious diseases remains modest. The diversity of new chemical entities specific for such targets has almost not increased over...

  • Yearly prevalence of primary metrodinazole and clarithromycin resistance of H. pylori: a prospective study in consecutive out-patients (Brussels 1995-2001). Burett, A.C.; Vandenborre, C.; Goutier, S. // Gut;Sep2002 Supplement 2, Vol. 51, pA92 

    Aim of the Study: The main determinants of anti-H. pylori (Hp) treatment success are patient compliance and the antimicrobial susceptibility of the infecting strains. The aim of this study is to follow the local prevalence of primary resistance to M and C in Hp isolates in Brussels. Method: All...

  • Traditional and Non-Traditional Antimicrobial Agents for H. Pylori Infection. Kato, Mototsugu; Hokari, Kaku; Kagaya, Hideotoshi; Takeda, Hiroshi; Sugiyama, Toshiro; Asaka, Masahiro // Current Pharmaceutical Design;Oct2000, Vol. 6 Issue 15, p1575 

    Triple therapy with a proton pump inhibitor plus two antibiotics is recently standard regimen for treatment of H. pylori infection. However, the agents that are used for H. pylori eardication are not always limited to drugs whose primary use is as an antimicrobial agent. Anti-H. pylori activity...

  • Past Antibiotic Use Affects Resistance and Outcomes of Helicobacter pylori Infection. Mcmahon, B.J.; Hennessy, T.W.; Bensler, J.M.; Bruden, D.L.; Parkinson, A.J.; Morris, J.M.; Reasonover, A.L.; Huriburt, D.A.; Bruce, M.G.; Sacco, F.; Butler, J.C. // Annals of Internal Medicine;9/16/2003, Vol. 139 Issue 6, pI10 

    Helicobacter pylori is a common type of bacteria that usually infects people during their childhoods. In most cases, the infection does not cause problems. However, some people with H. pylori infection get inflammation or ulcers in the stomach or upper intestine. Doctors treat inflammation and...

  • Natural polyphenols down-regulate universal stress protein in Mycobacterium tuberculosis: An in-silico approach. Aanandhi, M. Vijey; Bhattacherjee, Debojit; Gideon George, P. Samuel; Ray, Anirban // Journal of Advanced Pharmaceutical Technology & Research;Oct-Dec2014, Vol. 5 Issue 4, p171 

    Universal stress protein (USP) is a novel target to overcome the tuberculosis resistance. Our present study enlightens the possibilities of some natural polyphenols as an antioxidant for USP. The study has shown some molecular simulations of some selected natural antioxidants with USP. We have...

  • Interaction of wild type, G68R and L125M isoforms of the arylamine- N-acetyltransferase from Mycobacterium tuberculosis with isoniazid: a computational study on a new possible mechanism of resistance. Ramos, Ricardo; Perez, Janaína; Baptista, Luis; Amorim, Hermes // Journal of Molecular Modeling;Sep2012, Vol. 18 Issue 9, p4013 

    Isoniazid (INH) is a front-line drug used in the treatment of tuberculosis (TB), a disease that remains a major cause of death worldwide. Isoniazid is a prodrug, requiring activation in the mycobacterial cell by the catalase-peroxidase (CP) enzyme. Recent studies have suggested that acetylation...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics